In a study of mice and human brain tumours researchers at the University of the Michigan, Ann Arbor, searched for new treatments by exploring the reasons why some patients with gliomas live remarkably longer than others.

The results suggested that certain patients' tumour cells are less aggressive and much better at repairing DNA than others but are difficult to kill with radiation.

The researchers then showed that combining radiation therapy with cancer drugs designed to block DNA repair may be an effective treatment strategy.

The study was funded by the National Institutes of Health.

The researchers focused on low-grade gliomas that carry a disease-causing mutation in a gene called isocitrate dehydrogenase 1 (IDH1), which encodes a protein known to help cells produce energy.

This mutation is found in about 50 percent of cases of primary low-grade gliomas, a common and lethal form of brain tumour.

Glioma patients whose tumours have mutations in IDH1 are typically younger and live longer than those whose tumours have the normal gene.

These tumours also often have mutations in genes called TP53 (a tumour suppressor gene) and ATRX (a DNA-protein complex remodelling gene).

"Every year thousands of people are diagnosed with brain cancer and have little hope for long-term survival," said Maria G. Castro, Ph.D., professor of neurosurgery at Michigan Medicine and a senior author of the paper published in Science Translational Medicine.

"Our team's mission is to find life-saving treatments for these patients. The results from this study could be a blueprint for extending, if not saving, the lives of many patients."

The researchers recreated the patients' tumours by genetically engineering mice to grow brain cancer cells that have the disease-causing mutations in IDH1 along with mutations in TP53 and ATRX.

Like the patients, these mice lived longer than control mice whose tumours were programmed to have normal IDH1 while still harbouring the mutations in TP53 and ATRX.

When the research team examined the tumours, they found that the IDH1 mutation made the glioma cells less aggressive.

The cells divided at a lower rate than the controls and were much less likely to trigger tumour growth when implanted into mouse brains.

They also discovered that the IDH1 mutation, in the presence of mutations in TP53 and ATRX, made the tumours resistant to ionising radiation, a treatment that kills cells often by damaging DNA.

For instance, radiation exposure extended the lives of mice that were implanted with control tumours but had no effect on mice implanted with IDH1 mutant cells.

Further experiments provided a possible explanation for this resistance.

The results suggested the disease-causing mutation changed the activity of IDH1 which, in turn, triggered a cascade of chemical reactions that modified the cancer cells' genes in a way that increased the manufacture of proteins known to repair damaged DNA.

"Our results demonstrate that the metabolic changes caused by the IDH1 mutation reprograms brain cancer cells," said Dr. Castro.

These results led the researchers to formulate and test a new combination therapy.

They found that they could extend the lives of mice with mutant IDH1 tumours by exposing them to radiation while also injecting them with anti-cancer drugs designed to block DNA repair.

In contrast, treating these mice with either radiation or one of the drugs alone had no effect.

Several of the findings seen in mice were also seen in human gliomas grown in petri dishes.

"These findings have the potential to impact many younger glioma patients with low grade tumours by either 'curing' them or extending their lives," said Jane Fountain, Ph.D., program director, NIH's National Institute of Neurological Disorders and Stroke.

"The preclinical model Dr Castro's team developed will be extremely valuable to cancer researchers. It closely mirrors the human disease."

Source: National Institute of Neurological Disorders and Stroke